<DOC>
	<DOCNO>NCT00629083</DOCNO>
	<brief_summary>The primary purpose study demonstrate safety effectiveness Bulkamid® treatment stress urinary incontinence ( SUI ) due intrinsic sphincter deficiency ( ISD ) adult woman SUI stress predominant mix incontinence</brief_summary>
	<brief_title>Bulking Agents Treatment Stress Urinary Incontinence Females</brief_title>
	<detailed_description>The study single-masked , randomize , comparative multi-center , 2-arm parallel study intend demonstrate safety effectiveness Bulkamid® vs. Contigen® treatment stress urinary incontinence ( SUI ) due intrinsic sphincter deficiency ( ISD ) adult woman SUI stress predominant mixed incontinence . Subjects randomize receive either polyacrylamide hydrogel ( Bulkamid® ) treatment , collagen treatment ( Contigen® ) use 2:1 ratio mask treatment . Screening baseline evaluation collagen skin testing complete determine eligible subject . Following negative skin test , subject randomize treated Bulkamid® comparator device Treatment Visit . Subjects continent consider re-injection . A maximum 3 injection ( initial + 2 re-injections ) allow . After last injection , subject attend 3-Month , 6-Month 12-Month Follow-up Visits plus telephone contact 9 month . The study record objective incontinence measurement , subject 's perception effectiveness quality life assessment . Adverse event record throughout study . Each subject follow 12 month last injection .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence , Stress</mesh_term>
	<criteria>Be female 18 year age . Females childbearing potential &lt; 2 year postmenopausal must use 2 form contraception . Suffer SUI least 6 month . Have fail 2 previous noninvasive therapy 3 month . Have least 3 incontinence episode measure 3 day . Have baseline 24h pad test weight great equal 5 gm . Have VLPP ≤ 100 cm H2O . Have maximum cystometric capacity equal high ( ≥ ) 250 mL . Have PVR urine ≤ 100 mL . Have life expectancy 2 year . Has urethral hypermobility &gt; 30 deg . Has predominant urge incontinence . Has detrusor overactivity . Regularly intermittently users urethral catheter . Has previous radiation treatment pelvic floor . Has previous urethral surgery ( i.e . fistula , diverticulum ) urethral bulking . Failed sling colposuspension procedure least 6 month may include . Suffers known polyuria . Has three ( 3 ) cultureproven bacterial UTIs last 12 month . Has current infection ( urethritis , cystitis vaginitis ) . Has unevaluated hematuria . Has Prolapse Stage great II . Has BMI &gt; 35 kg/m2 . Is take pharmacological treatment stress urinary incontinence , 4 week prior screen . Is allergic bovine collagen . Is know suffer severe allergy anaphylaxis . Suffers autoimmune disease ( e.e . connective tissue disease ) could confound treatment . Is currently take take systemic corticosteroid within past 3 month . Currently cancer history cancer within past 5 year ( skin cancer evidence skin malignancy , least 2 year , include ) . Currently suffer unstable cardiovascular disease , cancer uncontrolled diabetes . Has active herpes genitalis . Is currently participate clinical trial participate another clinical trial within 3 month screening/baseline visit . Is pregnant , lactate intend become pregnant . Is physically able perform study procedure . Has neurogenic bladder Had vaginal delivery within 3 month prior screen .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>SUI</keyword>
	<keyword>Bulkamid</keyword>
	<keyword>Urinary Incontinence</keyword>
</DOC>